These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30611225)

  • 1. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin.
    You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
    BMC Cancer; 2019 Jan; 19(1):10. PubMed ID: 30611225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Prognostic Markers {CEA, Ca19.9, Neutrophil To Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)} With Progression Free Survival (PFS) in Advanced/Metastatic Gallbladder Carcinoma.
    Naik MD; Kataria SP; Kumar G; Singh R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of neutrophil-lymphocyte ratio and carbohydrate antigen 19-9 in patients with gallbladder carcinoma.
    Liu F; Hu HJ; Ma WJ; Yang Q; Wang JK; Li FY
    Medicine (Baltimore); 2019 Feb; 98(8):e14550. PubMed ID: 30813165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
    Ogul A; Kidi MM; Buyuksimsek M
    J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer.
    Hirooka Y; Ishikawa T; Kawashima H; Ohno E; Nonogaki K; Kanamori A; Hirai T; Uchida H; Shirai O; Ishikawa H; Goto H
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):119-125. PubMed ID: 28536803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
    Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
    BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
    J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.
    Sharma A; Kalyan Mohanti B; Pal Chaudhary S; Sreenivas V; Kumar Sahoo R; Kumar Shukla N; Thulkar S; Pal S; Deo SV; Pathy S; Ranjan Dash N; Kumar S; Bhatnagar S; Kumar R; Mishra S; Sahni P; Iyer VK; Raina V
    Eur J Cancer; 2019 Dec; 123():162-170. PubMed ID: 31707181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally-advanced and metastatic gallbladder cancer.
    Chatni SS; Sainani RS; Mehta SA; Mohandas KM
    J Cancer Res Ther; 2008; 4(4):151-5. PubMed ID: 19052386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy.
    Lee JW; Kim YT; Lee SH; Son JH; Kang JW; Ryu JK; Jang DK; Paik WH; Lee BS
    Gut Liver; 2018 Jan; 12(1):102-110. PubMed ID: 29069888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.
    Ostwal V; Swami R; Patkar S; Majumdar S; Goel M; Mehta S; Engineer R; Mandavkar S; Kumar S; Ramaswamy A
    Med Oncol; 2018 Mar; 35(4):57. PubMed ID: 29564657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis.
    Ramaswamy A; Ostwal V; Pinninti R; Kannan S; Bhargava P; Nashikkar C; Mirani J; Banavali S
    J Hepatobiliary Pancreat Sci; 2017 May; 24(5):262-267. PubMed ID: 28196310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.
    Doval DC; Sekhon JS; Gupta SK; Fuloria J; Shukla VK; Gupta S; Awasthy BS
    Br J Cancer; 2004 Apr; 90(8):1516-20. PubMed ID: 15083178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of combined preoperative PLR and CA19-9 in patients with resectable gallbladder cancer.
    Liu F; Wang JK; Ma WJ; Hu HJ; Lv TR; Jin YW; Li FY
    Updates Surg; 2024 Aug; 76(4):1235-1245. PubMed ID: 38436922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of neutrophil to lymphocyte ratio in patients with gallbladder carcinoma.
    Zhang L; Wang R; Chen W; Xu X; Dong S; Fan H; Liu C
    HPB (Oxford); 2016 Jul; 18(7):600-7. PubMed ID: 27346141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.